Search

Your search keyword '"Griesshammer M"' showing total 408 results

Search Constraints

Start Over You searched for: Author "Griesshammer M" Remove constraint Author: "Griesshammer M"
408 results on '"Griesshammer M"'

Search Results

1. Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine

4. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)

5. High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists

6. P1009: PREDICTORS OF HOSPITALIZATION AND SEVERE OUTCOMES IN PATIENTS WITH MPN AND COVID-19

7. P1055: CLINICAL AND GENETIC RESULTS OF THE PHASE IB/II TRIAL MPNSG-0212: RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA

8. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group

9. Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)

10. Determinants of early triage for hospitalization in MPN patients with COVID-19

14. Results from the phase-Ib/II combination trial MPNSG-0212 : Ruxolitinib plus pomalidomide in myelofibrosis with anemia

15. Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet

17. Correction:High-risk additional chromosomal abnormalities at low blast counts herald death by CML (Leukemia, (2020), 34, 8, (2074-2086), 10.1038/s41375-020-0826-9)

19. Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: A case-control study

20. Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin

21. Second cancers in MPN: Survival analysis from an international study

24. The German competence network ‘Acute and chronic leukemias’

25. Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon α and hydroxyurea

29. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

35. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

36. Abstract

46. Risk factors for secondary cancer in a case-control study on 1,881 patients with myeloproliferative neoplasms (ELN Study)

47. Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin

48. S1608 RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA: RESULTS FROM THE MPNSG-0212 COMBINATION TRIAL (NCT01644110)

49. PS1434 GENOMIC LANDSCAPE AND MOLECULAR RISK IN PATIENTS WITH DIPSS LOW- AND INTERMEDIATE-1-RISK PRIMARY MYELOFIBROSIS: A STUDY OF THE GERMAN STUDY GROUP FOR MYELOPROLIFERATIVE NEOPLASMS (GSG-MPN)

50. PS1468 IMPACT OF CYTOREDUCTIVE DRUGS ON SECOND CANCER IN MYELOPROLIFERATIVE NEOPLASMS

Catalog

Books, media, physical & digital resources